Hans-Christoph Diener1, Richard Bernstein2, Robert Hart3. 1. Department of Neurology, University Hospital Essen and Medical Faculty of the University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. hans.diener@uk-essen.de. 2. Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. McMaster University/Population Health Research Institute, 237 Barton Street East, HGH-DBCVSRI C4-105, Hamilton, ON, L8L 2X2, Canada.
Abstract
PURPOSE OF THE REVIEW: The purpose of the study was to review the literature on cryptogenic stroke and embolic stroke of undetermined stroke (ESUS). Cryptogenic stroke according to TOAST criteria is a stroke which is not due to cardiogenic embolism, small vessel disease with lacunes or large vessel disease of brain supplying arteries. In the context of secondary stroke prevention studies, cryptogenic stroke is not operationally defined. RECENT FINDINGS: The new concept of "embolic stroke of undetermined source" (ESUS) provides an operational definition. ESUS is diagnosed as a non-lacunar stroke on cerebral imaging and exclusion of large vessel atherosclerosis by CTA, MRA or ultrasound. Cardiogenic embolism is made less likely by ECG monitoring and echocardiography. At present, aspirin is used for secondary stroke prevention in patients with cryptogenic stroke. Based on the construct that ESUS might be caused by undetected atrial fibrillation or other embolic mechanisms, ongoing randomised secondary stroke prevention trials are comparing non-vitamin K oral anticoagulants (NOACs) with aspirin.
PURPOSE OF THE REVIEW: The purpose of the study was to review the literature on cryptogenic stroke and embolic stroke of undetermined stroke (ESUS). Cryptogenic stroke according to TOAST criteria is a stroke which is not due to cardiogenic embolism, small vessel disease with lacunes or large vessel disease of brain supplying arteries. In the context of secondary stroke prevention studies, cryptogenic stroke is not operationally defined. RECENT FINDINGS: The new concept of "embolic stroke of undetermined source" (ESUS) provides an operational definition. ESUS is diagnosed as a non-lacunar stroke on cerebral imaging and exclusion of large vessel atherosclerosis by CTA, MRA or ultrasound. Cardiogenic embolism is made less likely by ECG monitoring and echocardiography. At present, aspirin is used for secondary stroke prevention in patients with cryptogenic stroke. Based on the construct that ESUS might be caused by undetected atrial fibrillation or other embolic mechanisms, ongoing randomised secondary stroke prevention trials are comparing non-vitamin K oral anticoagulants (NOACs) with aspirin.
Entities:
Keywords:
Antiplatelet therapy; Cryptogenic stroke; Embolic stroke of undetermined source (ESUS); Non-vitamin K oral anticoagulants; Secondary stroke prevention
Authors: Hans-Christoph Diener; J Donald Easton; Christopher B Granger; Lisa Cronin; Christine Duffy; Daniel Cotton; Martina Brueckmann; Ralph L Sacco Journal: Int J Stroke Date: 2015-09-30 Impact factor: 5.266
Authors: David J Gladstone; Melanie Spring; Paul Dorian; Val Panzov; Kevin E Thorpe; Judith Hall; Haris Vaid; Martin O'Donnell; Andreas Laupacis; Robert Côté; Mukul Sharma; John A Blakely; Ashfaq Shuaib; Vladimir Hachinski; Shelagh B Coutts; Demetrios J Sahlas; Phil Teal; Samuel Yip; J David Spence; Brian Buck; Steve Verreault; Leanne K Casaubon; Andrew Penn; Daniel Selchen; Albert Jin; David Howse; Manu Mehdiratta; Karl Boyle; Richard Aviv; Moira K Kapral; Muhammad Mamdani Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Cesare Russo; Zhezhen Jin; Tatjana Rundek; Shunichi Homma; Ralph L Sacco; Marco R Di Tullio Journal: Stroke Date: 2009-06-04 Impact factor: 7.914
Authors: John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: Shyam Prabhakaran; Steven R Messé; Dawn Kleindorfer; Eric E Smith; Gregg C Fonarow; Haolin Xu; Xin Zhao; Barbara Lytle; Joaquin Cigarroa; Lee H Schwamm Journal: Neurol Clin Pract Date: 2020-10